CRIS Posts $0.00 EPS, $0.00 Revenue, Announces $80.8M PIPE Financing, TakeAim Lymphoma ORR 100% BTKi-Naïve, 37% BTKi-Experienced, Orphan Drug Designation, Phase 2 CLL Study Initiated
Curis Inc · Now $0.52
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS